StockData
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. (PMN) company profile

PMNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$3.21−0.10 (-3.02%)

Close on Nov 17, 2026Market cap $28.79MP/E –Yield –

About ProMIS Neurosciences

Pharmaceutical Preparations, SIC 2834

ProMIS Neurosciences develops therapeutic antibodies and vaccines targeting neurodegenerative and protein-misfolding disorders. Using its proprietary EpiSelect computational platform, the company predicts conformational disease-specific epitopes to generate humanized monoclonal antibodies and intrabodies that selectively neutralize neurotoxic misfolded proteins without disrupting healthy counterparts. Its pipeline includes PMN310, an antibody candidate undergoing clinical evaluation for Alzheimer’s disease designed to avoid monomer distraction and vascular plaque binding, alongside preclinical programs such as PMN267 for amyotrophic lateral sclerosis and frontotemporal lobar degeneration, and therapeutic candidates directed against alpha-synuclein for synucleinopathies.

The company conducts clinical development activities across multiple regions, having completed patient enrollment for its Phase 1b PRECISE-AD clinical study across 21 active clinical trial sites located in the United States. Preclinical research models and collaborative studies for its drug development programs have taken place in France, Belgium, and the United States. The company acquired technology licensing rights from the University of British Columbia, while the text does not disclose corporate headquarters or commercial facilities.

Summary of the business section of ProMIS Neurosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
ProMIS Neurosciences Inc.
Headquarters
Toronto, A6
Address
Suite 200, 1920 Yonge Street M4S 3E2
Phone
(416) 847-6898
Employees
30,000, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Z4
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, Tewksbury, Massachusetts

Stock & identifiers

Ticker
PMN
Exchange
Nasdaq
IPO date
Jan 10, 2007
Shares outstanding
9M, Aug 13, 2026
Public float
$29.70M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-25 reverse, Nov 28, 2025; 1-for-60 reverse, Jun 28, 2022
SEC CIK
1374339
CUSIP
74346M505
ISIN
CA74346M5054
FIGI
BBG000R0MF47
Share class FIGI
BBG001SMDG62
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Neil CashmanChief Scientific Officer, Director19,318
Neil K. WarmaChief Executive Officer, Director6,183
Ivana RubinoChief Commercial Officer–
Johanne KaplanChief Development Officer6,221
Max A. MilburyPrincipal Accounting Officer8,409
Larry Douglas AltstielChief Medical Officer–
Eugene WilliamsDirector40,213
Josh Mandel-BrehmDirector–
Madge K. ShafmasterDirector208,333
Slanix Paul AlexDirector6,058,738
William W. WymanDirector62,937
Patrick D. KirwinDirector10,093

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Neil Warma
CEO
$500.00K$104.00K$226.17K$830.17K-64%
Johanne Kaplan
Chief Development Officer
$386.67K$133.00K$62.20K$581.86K–
Larry Altstiel
Chief Medical Officer
$425.00K$57.00K$62.20K$544.20K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“It is estimated there are currently 30,000 people in the United States and 450,000 people worldwide, suffering from ALS, with approximately 5,000 new cases arising in the United States annually.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 8, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 5, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 29, 2022Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 22, 2022Spin-offRegistration as a new public company (Form 10), e.g. spin-off
Nov 3, 2014Name changeName changed from AMORFIX LIFE SCIENCES LTD to ProMIS Neurosciences Inc.

See a number that looks wrong?